Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BCX7353 as a Preventative Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema
Conditions
Interventions
BCX7353
Placebo
Locations
24
Australia
Adelaide, Australia
Campbelltown, Australia
Graz, Austria
Vienna, Austria
Québec, Canada
Toronto, Canada
Start Date
August 1, 2016
Primary Completion Date
August 1, 2017
Completion Date
August 1, 2017
Last Updated
March 23, 2021
NCT07298447
NCT06842823
NCT05396105
NCT05397431
NCT05469789
NCT07428499
Lead Sponsor
BioCryst Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions